Alan Glicklich, M.D.
About Alan Glicklich, M.D.
Alan Glicklich, M.D. (age 64) joined CalciMedica’s Board in January 2025 and is classified as a Class I director with a term expiring in 2027. He is currently Chief Medical Officer at Nuvig Therapeutics (since July 2023) and previously served as an independent clinical consultant to Nuvig (May 2022–July 2023). He holds a B.A. in Biology (University of Chicago), an M.D. (University of Wisconsin), and an MBA (Emory Goizueta) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Nuvig Therapeutics, Inc. | Chief Medical Officer | Since July 2023 | Leads clinical strategy for immune therapeutics |
| Nuvig Therapeutics, Inc. | Independent Clinical Consultant | May 2022–July 2023 | Supported clinical development pre-CMO appointment |
| Chinook Therapeutics, Inc. | Chief Medical Officer | May 2020–March 2022 | Built clinical, ops, medical affairs, biometrics, regulatory, PV; designed Phase 3 atrasentan in IgAN |
| Bird Rock Bio, Inc. | Chief Medical Officer | June 2015–April 2020 | Focused on mAb programs for inflammatory/fibrotic diseases |
| Arena Pharmaceuticals, Inc. | VP Clinical Development | Not disclosed (prior to 2015) | Designed Phase 2 programs (ralinepag in PAH; etrasimod in UC) |
| Bristol-Myers Squibb; Sanofi-Aventis; Regeneron | Various positions | Not disclosed | Early career experience in large-cap biopharma |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Nuvig Therapeutics, Inc. | Chief Medical Officer | Since July 2023 | Clinical-stage biotech in immune therapeutics |
| — | Other public company directorships | Not disclosed | No public board roles listed in biography |
Board Governance
- Independence: The Board determined that four of seven directors are independent under SEC/Nasdaq rules; the three non-independent are A. Rachel Leheny, Frederic Guerard, and Eric W. Roberts—implying Dr. Glicklich is independent .
- Committee structure: Audit and Compensation Committees are composed of Allan Shaw (Chair), Robert N. Wilson, and Fred Middleton; Nominating & Corporate Governance Committee is Robert N. Wilson (Chair) and Allan Shaw .
- Attendance culture: In 2024, the Board held five meetings; Audit five; Compensation four; Nominating one. No director then serving attended fewer than 75% of aggregate meetings. Independent directors meet in executive sessions regularly. (Note: Dr. Glicklich joined in 2025.) .
- Board leadership: Separate Chair (Robert N. Wilson) and CEO (A. Rachel Leheny) structure enhances oversight .
- Insider trading controls: Anti-hedging and anti-pledging restrictions apply to directors, with pre-approval required for any pledging .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual cash retainer (non-employee director) | $40,000 | Under former policy (May 2023) |
| Board Chair additional retainer | $35,000 | Applies to Chair only |
| Audit Committee member retainer | $7,500 | Chair retainer $15,000 (in lieu of member retainer) |
| Compensation Committee member retainer | $5,000 | Chair retainer $10,000 (in lieu of member retainer) |
| Nominating & Corporate Governance Committee member retainer | $5,000 | Chair retainer $10,000 (in lieu of member retainer) |
| Payment form flexibility | Board/Comp Committee may approve paying retainers in non-cash forms, effective March 26, 2025 | Beginning Jan 1, 2026, quarterly payments in arrears unless otherwise approved |
In April 2025, CalciMedica shifted Q1 and 2025 non-employee director retainers to stock options (contingent on shareholder approval of the Amended 2023 EIP), replacing cash for those periods .
Performance Compensation
| Award Type | Shares Granted | Vesting Start | Vesting Schedule | Exerciseability Condition | Notes |
|---|---|---|---|---|---|
| Contingent Award (annual grant) | 10,000 | March 26, 2025 | 1/12 monthly from grant date | Not exercisable prior to shareholder approval; forfeited if Proposal 3 not approved | Standard continuing director grant |
| Q1 Contingent Award (retainer in options) | 4,166 | Fully vested at grant | Fully vested at grant | Not exercisable prior to shareholder approval; forfeited if Proposal 3 not approved | Replaces Q1 2025 cash retainer |
| 2025 Contingent Award (retainer in options) | 15,000 | April 1, 2025 | 1/9 monthly from April 1, 2025 | Not exercisable prior to shareholder approval; forfeited if Proposal 3 not approved | Replaces Apr–Dec 2025 cash retainer |
| Total Additional Contingent Awards (Q1 + 2025) | 19,166 | As above | As above | Contingent on shareholder approval | Aggregate disclosed for Dr. Glicklich |
Equity awards were valued using Black-Scholes methodology for retainer conversions . Strike prices/expirations are not disclosed in the cited sections.
Other Directorships & Interlocks
| Entity | Relationship | Potential Interlock/Conflict |
|---|---|---|
| Sanderling Ventures (entities affiliated) | 17.7% beneficial owner of CALC | Board member Fred Middleton is Managing Director of Sanderling; no disclosed relationship to Dr. Glicklich |
| Valence Investments | 5.4% beneficial owner of CALC | Affiliations involve Leheny and Roberts; no disclosed relationship to Dr. Glicklich |
No other public company directorships for Dr. Glicklich are disclosed in his biography .
Expertise & Qualifications
- Clinical leadership across biotech and biopharma with proven Phase 3 study design and operational execution (e.g., atrasentan in IgA nephropathy) .
- Broad therapeutic experience: chronic inflammatory, autoimmune, and chronic kidney diseases; monoclonal antibodies; small molecules .
- Education: B.A. Biology (University of Chicago), M.D. (University of Wisconsin), MBA (Emory Goizueta) .
Equity Ownership
| Holder | Shares Beneficially Owned (#) | % of Outstanding | Notes |
|---|---|---|---|
| Alan Glicklich, M.D. | 2,222 | <1% | Footnote: Consists solely of shares acquirable within 60 days via option exercise |
| Shares Outstanding (reference for % calc) | 13,971,990 | — | As of March 31, 2025 |
No disclosures of pledged shares, hedging, or margin accounts for Dr. Glicklich; company policy prohibits hedging and pledging without pre-approval .
Governance Assessment
- Independence and role: Dr. Glicklich is independent under SEC/Nasdaq standards, supporting board oversight quality .
- Committee engagement: Current committee compositions list Wilson/Shaw on Nominating & Corporate Governance and Shaw/Wilson/Middleton on Audit/Compensation; no committee assignment for Dr. Glicklich is disclosed in these sections (biography header references a Nominating & Corporate Governance Committee tie, but composition lists only two members) .
- Alignment and ownership: Beneficial ownership is de minimis (2,222 options exercisable within 60 days), with incremental alignment from new option grants; low near-term “skin-in-the-game” compared to major holders .
- Pay structure and signals: 2025 shift of director retainers from cash to options increases equity linkage; while supportive of alignment, options in lieu of cash can be viewed as a modest red flag for independence if used persistently (market practice favors a mix of cash retainer and equity) .
- Board leadership and risk controls: Separation of Chair/CEO and robust anti-hedging/anti-pledging policy are positive governance indicators .
- Conflicts/related-party exposure: No related-party transactions involving Dr. Glicklich are disclosed; major investor and director affiliations are transparent (Sanderling, Valence) with no stated ties to him .
- Attendance: The Board’s 2024 attendance record indicates strong engagement; Dr. Glicklich joined in 2025, so his attendance will be assessed prospectively .
RED FLAGS: Persistent replacement of director cash retainers with options could raise independence concerns if not temporary; low personal share ownership reduces immediate alignment, though scheduled vesting will increase exposure .